---
title: Ultrafine particle toxicity
layout: default
permalink: /markopolo/
---

# Fine and ultrafine particle toxicity
## ExposomeMap-UFP

**Development status:** Active development  
**Diseases:** Multiple related diseases  
**Sustainable support:** [LIH](https://www.lih.lu/), [MINERVA](https://minerva.pages.uni.lu/)  
**Construction tools:** [yEd Graph Editor](https://www.yworks.com/products/yed), [CellDesigner](https://www.celldesigner.org/)  
**Funding:** [Grant Agreement No. 101156161](https://cordis.europa.eu/project/id/101156161), [https://markersofpollution-markopolo.eu/](https://markersofpollution-markopolo.eu/)  
**License:** [Creative Commons Attribution 4.0 International (CC BY 4.0) License](https://creativecommons.org/licenses/by/4.0/)  
**Contact:** Petr Nazarov, Luxembourg Institute of Health, petr.nazarov(at)lih.lu  

### Description

The ExposomeMap-UFP effort is initiated within the [MARKOPOLO](https://markersofpollution-markopolo.eu/) project that aims to "identify disease-relevant biomarkers and causality mechanisms to understand the biological pathways of cerebral, pulmonary and cardiovascular health outcomes" towards improving risk assessment and allowing evaluation of the effectiveness of mitigation strategies.

The ExposomeMap-UFP is an open, FAIR-compliant model that connects particle exposure with biological mechanisms and health outcomes. The model highlights critical steps such as oxidative stress, inflammation and barrier disruption, which together contribute to various conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and neurodegenerative diseases.

### Diseases

Related conditions include 
**respiratory diseases:** 
asthma ([DOID:2841](https://disease-ontology.org/?id=DOID:2841)), 
COPD ([DOID:3083](https://disease-ontology.org/?id=DOID:3083)); 
**cardiovascular diseases:** 
stroke ([DOID:6713](https://disease-ontology.org/?id=DOID:6713)), 
heart attack ([DOID:5844](https://disease-ontology.org/?id=DOID:5844)), 
hypertension ([DOID:10763](https://disease-ontology.org/?id=DOID:10763)); 
**neurodegenerative diseases:** 
Alzheimer's disease ([DOID:10652](https://disease-ontology.org/?id=DOID:10652)), 
Parkinson's disease ([DOID:14330](https://disease-ontology.org/?id=DOID:14330)), 
dementia ([DOID:1307](https://disease-ontology.org/?id=DOID:1307)); 
**skin diseases:** 
atopic dermatitis ([DOID:2723](https://disease-ontology.org/?id=DOID:2723)); 
**degenerative joint diseases:** 
osteoarthritis ([DOID:8398](https://disease-ontology.org/?id=DOID:8398)); 
**autoimmune diseases:** 
rheumatoid arthritis ([DOID:7148](https://disease-ontology.org/?id=DOID:7148)), 
multiple sclerosis ([DOID:2377](https://disease-ontology.org/?id=DOID:2377)), 
inflammatory bowel disease ([DOID:0050589](https://disease-ontology.org/?id=DOID:0050589)).

<!--Related conditions include: <br>
**respiratory diseases:** <br>
asthma ([DOID:2841](https://disease-ontology.org/?id=DOID:2841)), 
COPD ([DOID:3083](https://disease-ontology.org/?id=DOID:3083)), <br>
**cardiovascular diseases:** <br>
stroke ([DOID:6713](https://disease-ontology.org/?id=DOID:6713)), 
heart attack ([DOID:5844](https://disease-ontology.org/?id=DOID:5844)), 
hypertension ([DOID:10763](https://disease-ontology.org/?id=DOID:10763)), <br>
**neurodegenerative diseases:** <br>
Alzheimer's disease ([DOID:10652](https://disease-ontology.org/?id=DOID:10652)), 
Parkinson's disease ([DOID:14330](https://disease-ontology.org/?id=DOID:14330)), 
dementia ([DOID:1307](https://disease-ontology.org/?id=DOID:1307)), <br>
**skin diseases:** <br>
atopic dermatitis ([DOID:2723](https://disease-ontology.org/?id=DOID:2723)), <br>
**degenerative joint diseases:** <br>
osteoarthritis ([DOID:8398](https://disease-ontology.org/?id=DOID:8398)), <br>
**autoimmune diseases:** <br>
rheumatoid arthritis ([DOID:7148](https://disease-ontology.org/?id=DOID:7148)), 
multiple sclerosis ([DOID:2377](https://disease-ontology.org/?id=DOID:2377)), 
inflammatory bowel disease ([DOID:0050589](https://disease-ontology.org/?id=DOID:0050589)), <br>
and many others.-->

### Editorial Panel

### Development Team

<table>
  <!--
<tr>
<td style="width: 105px;"><img src="../images/team/AlexanderMazein.jpg" alt="Alexander Mazein" /></td>
<td><strong>Alexander Mazein, PhD</strong><br /><strong>Luxembourg Institute of Health, Luxembourg</strong><br />
Researcher at the Multi-omics Data Science Research Group</td>
</tr>
<tr>
<td style="width: 105px;"><img src="../images/team/MarekOstaszewski.jpg" alt="Marek Ostaszewski" /></td>
<td><strong>Marek Ostaszewski, PhD</strong><br /><strong>University of Luxembourg, Luxembourg</strong><br />
Research Scientist at the Luxembourg Centre for Systems Biomedicine</td>
</tr>
<tr>
<td style="width: 105px;"><img src="../images/team/AhmedHemedan.jpg" alt="Ahmed Hemedan" /></td>
<td><strong>Ahmed Hemedan, PhD</strong><br /><strong>Luxembourg Institute of Health, Luxembourg</strong><br />
Postdoctoral Fellow at the Department of Transversal Translational Medicine</td>
</tr>
  -->
<tr>
<td style="width: 105px;"><img src="../images/team/PetrNazarov.jpg" alt="Petr Nazarov" /></td>
<td><strong>Petr Nazarov, PhD</strong><br /><strong>Luxembourg Institute of Health, Luxembourg</strong><br />
Head of the Bioinformatics and AI Unit</td>
</tr>
</table>

### Acknowledgements

The project is developing in collaboration with the [Luxembourg Centre for Systems Biomedicine](https://www.uni.lu/lcsb-en/) and is supported by the [MINERVA Platform](https://minerva.pages.uni.lu/doc/) (Molecular Interaction NEtwoRk VisuAlization) and the [ELIXIR Luxembourg](https://elixir-luxembourg.org/) tools and services. 

### Funding

This work is supported by the environmental research consortium [MARKOPOLO](https://markersofpollution-markopolo.eu/) under the HORIZON call HLTH-2024-ENVHLTH-02-06 ([Grant Agreement Number 101156161](https://cordis.europa.eu/project/id/101156161)) funded by the European Union and the Swiss State Secretariat for Education, Research and Innovation (SERI).

<!-- The work was also supported by the environmental research consortium MARKOPOLO, which is funded by the European Union (grant agreement number 101156161) and the Swiss State Secretariat for Education, Research and Innovation (SERI). Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union, the European Health and Digital Executive Agency (HADEA) or the SERI. Neither the European Union nor the granting authorities can be held responsible for them.-->

<!--The work was supported by the environmental research consortium MARKOPOLO, which is funded by the European Union (Grant Agreement Number 101156161) and the Swiss State Secretariat for Education, Research and Innovation (SERI). Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union, the European Health and Digital Executive Agency (HADEA) or the SERI. Neither the European Union nor the granting authorities can be held responsible for them.-->

<!--The work is supported by the environmental research consortium MARKOPOLO under the HORIZON call HLTH-2024-ENVHLTH-02-06 (Grant Agreement Number 101156161) funded by the European Union and the Swiss State Secretariat for Education, Research and Innovation (SERI).-->
